🛒 MindNetQ / MindNetQ Cortex — Products & Pricing
Free 7-Day Trial — Sign up and run Cortex on your targets. No commitment. Start Free Trial →
1. Platform in Plain Language
| Area | Explanation |
|---|
| What it does | Scans about 19,000 human genes across six biological data layers, finds genes abnormally active in cancer, explains why they are active, and maps the mechanism to drug classes that already exist. |
| What it produces | Novel biomarker candidates, mechanism-backed companion diagnostics, drug repurposing links, prognostic biomarkers, and governed evidence packages for clinical and regulatory use. |
| Why it is different | Every decision is hash-chained and replayable, so results are not black-box outputs. The platform uses governed AI, cross-modal filtering, and evidence-led review before a result is packaged. |
2. Services Pricing
| Offering | Timeline | Price | What you get |
|---|
| Feasibility Study | 2 weeks | $15K | Quick signal check on your dataset with a yes, maybe, or no answer. |
| Discovery Pilot | 6 weeks | $40K | Full governed pipeline run with novel candidates, mechanism analysis, drug links, and governed evidence package. |
| Multi-Cohort Evaluation | 8 weeks | $150K | Signal applied across 2 to 3 patient cohorts with subgroup and outcome comparison. |
| Validation Protocol Design | Project-based | $25K | Wet-lab validation protocol design for your biomarker. |
| Analytical Support | Monthly | $10K/month | Computational support during lab validation, including reanalysis and evidence updates. |
| Regulatory Evidence Package | Project-based | $50K | FDA-ready evidence package with governed evidence chain and reproducibility support. |
| Clinical Validation Engagement | 4 to 6 weeks | $300K–$400K | Apply signals, generate patient scores, compare to outcomes, analyze subgroups, and deliver a decision-ready recommendation. |
3. Platform Access & Deployment
| Offer | Price | What you get |
|---|
| Explorer | $60K/year | 2 discovery runs per year, dashboard access, quarterly reports. |
| Professional | $180K/year | Unlimited runs, priority support, custom signal development, API access. |
| Enterprise | $500K/year | Dedicated instance, multi-cancer scanning, integration with your data systems, named support team. |
| On-Premise Deployment | $250K + $120K/year | MindNetQ Cortex deployed inside your infrastructure so data stays inside your network. |
| Federated Multi-Site | $500K + $200K/year | Governed federated learning across sites with no raw data shared between sites. |
4. MindNetQ Technology (GPU-Scalable AI Governance)
Distributed GPU-scalable AI governance platform. Service sharding, authority management, evidence chains, quantum gate. Governs any AI workload at scale.
| Tier | Price | What you get |
|---|
| Standard | $5,000/mo | Single-shard · 1 GPU · 10 governed pipelines · Managed cloud |
| Multi-Shard | $25,000/mo | Up to 8 shards · 4 GPUs · Unlimited pipelines · Custom governance rules |
| Custom Shard | $50K–$150K/mo | Dedicated shards · Custom topology · On-prem/hybrid · SLA · Dedicated engineer |
| Enterprise | Contact | Full deployment · Unlimited shards · White-label · 24/7 support |
Sharding options: by workload · by tenant · by geography · by authority level
5. E-DICE Core (Governance SDK)
Embed bounded decision-making into any AI system. Authority contraction/expansion, quantum decision memory, confidence modules. Python · Rust · C/ASM.
| Tier | Price | What you get |
|---|
| Developer | $2,500/mo per seat | SDK access · Python + Rust · Documentation · Community support |
| Team | $10,000/mo (5 seats) | Full SDK · Priority support · Custom module configuration |
| Enterprise | $25,000+/mo | Unlimited seats · C/ASM modules · On-prem · Dedicated integration |
6. Diagnostic & Prognostic Signals
| # | Gene | Type | Signal | Drug Class | Scope | Prior Pubs |
|---|
| 1 | PRR36 | Diagnostic | 3.7x prostate, 4.4x breast, 11.6x lung, 14.1x colon | BET inhibitors | Pan-cancer (4+ MF) | 0 in 18 types |
| 2 | DNAH5 | Diagnostic | 4.4x prostate, 3.16x colon | BET inhibitors | Prostate + colon | 0 in prostate |
| 3 | ARSF | Prognostic | High = 687d vs 1302d survival | Sulfatase inhibitors | Prostate | 0 in any cancer |
| 4 | TM7SF2 | Prognostic (protective) | High = 1249d vs 653d survival | TBD | Prostate | 0 in prostate |
| 5 | STX19 | Diagnostic | 2.35x prostate | EGFR inhibitors | Prostate | 0 in any cancer |
Product Packages by Signal
| Signal | Biology (plain language) | Commercial Package |
|---|
| PRR36 / DNAH5 | Enhancer-override biology. Some tumors turn on genes through nearby DNA control switches called enhancers. BET inhibitor drugs shut down that switch activity. | Evaluation, exclusive license, non-exclusive license, co-development. |
| STX19 | EGFR trafficking biology. STX19 helps move EGFR receptors inside cells. Higher STX19 may indicate stronger EGFR signaling and better fit for EGFR-targeted therapy. | Evaluation, exclusive license, non-exclusive license. |
| ARSF | High ARSF tracks with worse survival and may support sulfatase inhibitor biology. | Evaluation and license. |
| TM7SF2 | Higher TM7SF2 appears linked to better survival and helps identify lower-risk biology. | Protective prognostic package. |
7. Kit Pricing
| Kit | Evaluation | License |
|---|
| PRR36 / DNAH5 | $40K biotech / $250K mid pharma / $500K big pharma | Exclusive: $250K + 4% royalty. Non-exclusive: $100K + 3%. Co-dev: $0 + 8%. |
| STX19 | $40K biotech / $250K mid pharma / $500K big pharma | Exclusive: $200K + 4%. Non-exclusive: $80K + 3%. |
| ARSF | $40K / $250K / $500K | License: $150K + 4% royalty. |
| Custom Signal Development | New: $80K. Validation: $40K. | Future license after validation. |
8. Therapeutic Programs (Licensing)
| Program | Compounds | Status | Price |
|---|
| METAP1D (first-in-class) | 12 | 8 advanced + 4 Grade A, quantum-validated | $500K + milestones + royalties |
| CRYZ (first-in-class) | 100 | 2 wet lab ready + 3 Grade A + 95 candidates | $500K + milestones + royalties |
| ATP1A4 | 3 | Grade A, early stage | $250K co-development |
| BRD4/BET (parked) | 223 | Novel scaffolds, best Vina -11.24 | $50K–$150K non-exclusive |
9. Why the Pricing Is Justified
| Value Area | Why It Supports Price |
|---|
| Governed execution | Every decision is auditable and replayable. Lowers discovery risk and increases trust for regulated and clinical use. |
| Discovery value | Producing novel biomarkers with zero prior publications and linking them to drug classes and mechanisms. |
| Validation value | Signals packaged for outcome comparison, subgroup analysis, and companion diagnostic development. |
| IP value | Patented governed methodology, model orchestration, and invention-backed discovery outputs — not commodity bioinformatics. |
10. External Explanation Guardrails
✅ Do Say
• Governed AI platform for cancer biomarker discovery
• Every decision is auditable and replayable
• Novel biomarkers with zero prior publications
• Mechanism-backed, not just correlation
• Connects to existing approved drugs
• Patent-protected methodology
❌ Do Not Say
• Specific enhancer coordinates or methylation values
• Internal model names or numbers
• Specific patent claim numbers
• Quantum circuit details
• Sentinel architecture details
• Anything about unfiled IP
Standard Responses
"How does it work?" — Our platform integrates six layers of biological data for every human gene, identifies which genes are abnormally active in cancer, determines the regulatory mechanism driving that activity, and maps it to existing drug classes. Every step is governed through a patented delegation system that makes the analysis auditable and reproducible.
"Why should I trust it?" — Every analytical decision is hash-chained into a tamper-evident evidence ledger. You can replay the analysis from raw data to final conclusion and get the same result. This is the level of reproducibility needed for regulatory submission.
"Why this price?" — Our pricing reflects discovery value. These are novel biomarkers nobody else has found, connected to existing drugs through a patented governed methodology. The evaluation lets a partner test the signal on its own data before committing to a license.
Contact: sales@mindnetq.com · partnerships@mindnetq.com
Confidential — Internal Use Only
Pricing — Two Entry Points
| Service | Price | What You Get |
|---|
| Cortex Basic | $500/mo | 10 queries, reasoning, public data, 7-day trial |
| Cortex Pro | $5,000/mo | 100 queries, private memory, monitoring, API |
| MindNetQ Cortex Research Job | $500-$2K/job | Full multi-omics pipeline, real-time, Research Object |
| Institutional | $50-150K/yr | Unlimited users, private datasets, federated |
| Enterprise | $250-500K/yr | Dedicated shard, SLA, HIPAA, custom modules |
| Quantum VQE Run | $5,000/run | IonQ binding energy, error mitigation, 200 restarts, human-approved |
| Quantum Package (5) | $25,000 | 5 VQE runs, bulk discount |